Want to see JP:7776 full AI Analyst Report?
CellSeed Inc. (7776) AI Stock Analysis
CellSeed Inc.
(TSE/TYO:7776)
The stock scores at the lowest possible level due to severe fundamental deterioration and persistent technical weakness. The company is deeply unprofitable, burning cash rapidly, and its equity base is shrinking. The stock is in a clear downtrend across all timeframes, with no valuation or income support. The risk of financial distress is high without a significant turnaround or new funding.
CellSeed Inc. (7776) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 6.94B
- Dividend Yield
- ―
- Average Volume (3M)
- 173.46K
- Price to Earnings (P/E)
- -5.5
- Beta (1Y)
- 1.04
- Revenue Growth
- -56.16%
- EPS Growth
- 3.12%
- Country
- Japan
- Employees
- 36
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
CellSeed Inc. Business Overview & Revenue Model
Company Description
CellSeed Inc. focuses on pioneering regenerative therapies that utilize cell sheet technology. The company is deeply involved in the research, development, and market introduction of advanced cell-sheet medicine products. Its innovations encompass ep...
CellSeed Inc. Financial Statement Overview
Summary
Financial performance is critically weak. Revenue declined 56.7%, net losses exceed total revenue, and cash burn is severe with negative operating and free cash flow. The low debt is the only positive, but equity is eroding rapidly.
Income Statement
20Very NegativeBalance Sheet
35NegativeCash Flow
18Very Negative| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 83.68M | 193.28M | 190.13M | 126.43M | 161.67M |
| Gross Profit | 42.75M | 110.11M | 107.16M | 61.02M | 84.04M |
| EBITDA | -1.05B | -855.49M | -836.52M | -750.00M | -905.67M |
| Net Income | -1.10B | -859.84M | -846.53M | -759.68M | -912.87M |
Balance Sheet | |||||
| Total Assets | 1.66B | 2.43B | 2.47B | 1.54B | 1.41B |
| Cash, Cash Equivalents and Short-Term Investments | 1.32B | 2.13B | 2.16B | 1.07B | 846.67M |
| Total Debt | 132.92M | 143.75M | 151.25M | 158.75M | 160.00M |
| Total Liabilities | 387.46M | 269.88M | 301.05M | 365.58M | 363.58M |
| Stockholders Equity | 1.27B | 2.16B | 2.16B | 1.18B | 1.04B |
Cash Flow | |||||
| Free Cash Flow | -1.02B | -884.47M | -801.07M | -733.60M | -908.15M |
| Operating Cash Flow | -988.98M | -866.10M | -779.43M | -718.01M | -817.15M |
| Investing Cash Flow | -26.72M | -18.37M | 56.31M | 61.73M | -110.44M |
| Financing Cash Flow | 200.30M | 855.48M | 1.81B | 881.81M | 396.88M |
CellSeed Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7776, the sentiment is Negative. The current price of 172.00 is below the 20-day moving average (MA) of 198.30, below the 50-day MA of 214.48, and below the 200-day MA of 256.93, indicating a bearish trend. The MACD of -8.69 indicates Positive momentum. The RSI at 30.68 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7776.
CellSeed Inc. Peers Comparison
Overall Rating
JP:709667Neutral
JP:459348Neutral
JP:497844Neutral
JP:777442Neutral
JP:459938Underperform- JP:777637Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:7096 | 67Neutral | JPY 7.02B | 45.85 | ― | ― | 4.85% | -40.57% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| JP:4593 | 48Neutral | JPY 34.43B | 45.77 | ― | ― | -47.32% | ― |
| JP:4978 | 44Neutral | JPY 12.39B | -22.88 | ― | ― | -18.71% | -246.54% |
| JP:7774 | 42Neutral | JPY 24.65B | -65.42 | ― | ― | 17.05% | 10.47% |
| JP:4599 | 38Underperform | JPY 8.15B | -3.77 | ― | ― | ― | 4.85% |
| JP:7776 | 37Underperform | JPY 7.18B | -5.52 | ― | ― | -56.16% | 3.12% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:7776 | CellSeed Inc. | 172.00 | -251.00 | -59.34% | |
| JP:4593 | Healios KK | 245.00 | -222.00 | -47.54% | |
| JP:4599 | StemRIM Inc. | 123.00 | -150.00 | -54.95% | |
| JP:4978 | ReproCELL Inc. | 113.00 | -55.00 | -32.74% | |
| JP:7096 | StemCell Institute | 694.00 | -108.00 | -13.47% | |
| JP:7774 | Japan Tissue Engineering Co., Ltd. | 601.00 | 138.00 | 29.81% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 06, 2026